Sam Brusco, Associate Editor01.25.24
Medical robotics company Noah Medical announced the 500th use of its Galaxy system in the U.S. took place. The procedure was conducted at CHI Memorial in Chattanooga by Dr. Krish Bhadra.
Noah Medical said the procedure marks a crucial step in the U.S. commercial rollout of its image-integrated, robotic-assisted bronchoscopy system. The Galaxy system includes integrated tomosynthesis (TiLT technology) with augmented fluoroscopy, a disposable single-use bronchoscope with always-on vision, and a small footprint for easy integration into bronchoscopy suites.
The company said recent preclinical trial results demonstrated Galaxy could achieve 100% successful navigation to lesion, 100% diagnostic yield, and 95% tool-in-lesion accuracy. In human trial, Galaxy achieved 90-95% diagnostic yield.
The robotic system’s first U.S. procedure took place at University of Chicago Medicine in May 2023, two months after its U.S. Food and Drug Administration (FDA) approval.
Dr. Bhadra said finding and successfully performing a biopsy with today’s tools and first-generation robotics may resemble flying an airplane blindfolded. “The Galaxy System fundamentally changes the game, making our work clear and obvious,” he said. “Congratulations to the Noah Medical team on achieving this important milestone.”
“Congratulations to Dr. Bhadra and the team at CHI Memorial for adopting and advancing image-integrated robotic assisted bronchoscopy,” said Jian Zhang, Ph.D., Noah Medical founder and CEO. “Our journey to 500 successful cases in the U.S. using the Galaxy System is just the beginning. We are improving patient care, transforming clinical workflow, and contributing to the future of healthcare.”
Last June, Noah Medical pocketed $150 million from Series B funding. The company said it plans to use the funds to meet rising demand for Galaxy.
Noah Medical said the procedure marks a crucial step in the U.S. commercial rollout of its image-integrated, robotic-assisted bronchoscopy system. The Galaxy system includes integrated tomosynthesis (TiLT technology) with augmented fluoroscopy, a disposable single-use bronchoscope with always-on vision, and a small footprint for easy integration into bronchoscopy suites.
The company said recent preclinical trial results demonstrated Galaxy could achieve 100% successful navigation to lesion, 100% diagnostic yield, and 95% tool-in-lesion accuracy. In human trial, Galaxy achieved 90-95% diagnostic yield.
The robotic system’s first U.S. procedure took place at University of Chicago Medicine in May 2023, two months after its U.S. Food and Drug Administration (FDA) approval.
Dr. Bhadra said finding and successfully performing a biopsy with today’s tools and first-generation robotics may resemble flying an airplane blindfolded. “The Galaxy System fundamentally changes the game, making our work clear and obvious,” he said. “Congratulations to the Noah Medical team on achieving this important milestone.”
“Congratulations to Dr. Bhadra and the team at CHI Memorial for adopting and advancing image-integrated robotic assisted bronchoscopy,” said Jian Zhang, Ph.D., Noah Medical founder and CEO. “Our journey to 500 successful cases in the U.S. using the Galaxy System is just the beginning. We are improving patient care, transforming clinical workflow, and contributing to the future of healthcare.”
Last June, Noah Medical pocketed $150 million from Series B funding. The company said it plans to use the funds to meet rising demand for Galaxy.